Publications

5674 Results

Fractures in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG S0307 trial (ClinicalTrials.gov Identifier: NCT00127205)

Authors
R Yung;J Miao;AHG Paterson;M Clemons;E Dees;JN Ingle;CI Falkson;W Barlow;G Hortobagyi;J Gralow
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 10-14, 2019, San Antonio, TX), P2-18-03, poster
Year
2019
Research Committee(s)
Breast
Study Number(s)
S0307

Baseline Factors Associated with Aromatase Inhibitor Adherence Failure among Women in Enrolled in a Randomized Trial of Text-Messaging: SWOG S1105

Authors
DL Hershman;JM Unger;A Moseley;G Clarke Hillyer;K Arnold;JR Gralow;NL Henry;S Ramsey;A Neugut
Journal / Conference
San Antonio Breast Cancer Symposium (Dec 10-14, 2019, San Antonio, TX), poster, spotlight session
Year
2019
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S1105

Increasing lengths of first complete remission with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data

Authors
M Othus;G Garcia-Manero;JE Godwin;JK Weick;F Appelbaum;H Erba;E Estey
Journal / Conference
Blood (2019) 134 (Supplement_1): 291, abst 613 (American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S0106, S1203, SWOG-8600, SWOG-9031, SWOG-9333

Alliance A041701 - A randomized phase 2/3 study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute myeloid leukemia receiving intensive induction chemotherapy

Authors
G Uy;V Yin;H Klepin;S Dinner;A Jaslowski;SA Strickland;J Liesveld;J Byrd;RM Stone
Journal / Conference
Blood (2019) 134 (Supplement_1): 1366. American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), TIPS, poster
Year
2019
Research Committee(s)
Leukemia

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Authors
M Smith;O Jegede;SS Parekh;C Hanson;F Kuhr;P Martin;B Till;M Crump;JP Leonard;JW Friedberg;B Kahl;T Witzig
Journal / Conference
Blood (2019) 134 (Supplement_1): 751, abst 623; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/E1411

Factors That Potentially Impact Lenalidomide/R-CHOP (R2-CHOP) Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Authors
G Nowakowski;A Chiappella;F Hong;R Gascoyne;DW Scott;W Macon;RL King;JE Amengual;RF Little;JP Leonard;JW Friedberg;L Kostakoglu;W Jurczak;K Yamamoto;M Czuczman;J Russo;K Hudak;J Zhang;S Wade;T Witzig;BS Kahl;U Vitolo
Journal / Conference
Blood (2019) 134 (Supplement_1): 4092, abst 626; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/E1412

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup NCTN Study S1001

Authors
D Persky;H Li;D Stephens;SI Park;NL Bartlett;L Swinnen;P Barr;J Winegarden;L Constine;TJ Fitzgerald;JP Leonard;BS Kahl;M Leblanc;J Song;RI Fisher;L Rimsza;SM Smith;JW Friedberg
Journal / Conference
Blood (2019) 134 (Supplement_1): 349; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
S1001

Intraclonal Heterogeneity Caused by Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: an Analysis of SWOG S0016

Authors
WR Burack;H Li;D Adlowitz;J Spence;L Rimsza;R Braziel;C Spier;M Kaminski;JP Leonard;RI Fisher;M Leblanc;SM Smith;JW Friedberg
Journal / Conference
Blood (2019) 134 (Supplement_1): 2771; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
S0016

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Authors
A Hay;S Assouline;R Walter;RF Little;A Moseley;G Sperling;A Im;J Foran;J Radich;M Fang;HP Erba;L Michaelis
Journal / Conference
Blood (2019) 134 (Supplement_1): 3905; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S1612

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Authors
A Advani;A Moseley;M Liedtke;M O'Donnell;I Aldoss;M Mims;K O'Dwyer;M Othus;HP Erba
Journal / Conference
Blood (2019) 134 (Supplement_1): 227; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S1312